title: Randomised comparison of the FerX Ella antireflux stent and the ultraflex stent: proton pump inhibitor combination for prevention of post-stent reflux in patients with esophageal carcinoma involving the esophago-gastric junction.
abstract: OBJECTIVE
  Metal stents placed across the gastroesophageal junction in patients with malignant dysphagia frequently present with reflux symptoms. We compared an antireflux stent with a standard open stent used in combination with proton pump inhibitor medication.
  
  
  METHODS
  Forty-nine patients with dysphagia due to inoperable carcinoma in the lower third of the esophagus were randomly selected to receive either a antireflux valve stent (FerX-Ella) (n = 22) or a covered standard open stent (Ultraflex), which was combined with proton pump inhibitors such as omeprazole (n = 26). The technical success, the presence of reflux, and complications were recorded.
  
  
  RESULTS
  Reflux was seen in 3/22 patients (13.6%) in the FerX-Ella group and in 2/26 patients (7.7%) in the Ultraflex and proton pump inhibitor combination group (P-value not significant). In both groups, a significant improvement in the dysphagia score was seen and no statistically significant difference was detected between the two groups (P = 0.84). The FerX-Ella stents migrated more frequently (32%) than the Ultraflex stents (23%). This also necessitated surgical intervention more frequently in the FerX-Ella group (2/22, 9.1%) compared to the Ultraflex group (1/26, 3.8%).
  
  
  CONCLUSIONS
  The antireflux stent had no demonstrable advantages compared to the combination of standard open stent and proton pump inhibitor medication.
authors.affiliation: Department of Radiology, Guy's and St Thomas' Hospital, NHS Foundation, London, UK.
authors.forename: Tarun
authors.initials: T
authors.lastname: Sabharwal
authors.forename: Manpreet S
authors.initials: MS
authors.lastname: Gulati
authors.forename: Nikolas
authors.initials: N
authors.lastname: Fotiadis
authors.forename: Renato
authors.initials: R
authors.lastname: Dourado
authors.forename: Abrie
authors.initials: A
authors.lastname: Botha
authors.forename: Robert
authors.initials: R
authors.lastname: Mason
authors.forename: Andreas
authors.initials: A
authors.lastname: Adam
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D054855:Drug-Eluting Stents; D004938:Esophageal Neoplasms / Q000150:complications*; D004943:Esophagogastric Junction; D005260:Female; D005764:Gastroesophageal Reflux / Q000209:etiology* / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000628:therapy*; D011446:Prospective Studies; D011474:Prosthesis Design; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*
chemical_list: D054328:Proton Pump Inhibitors; D009853:Omeprazole